Certified by Founder
Lodge
Adcendo
start up
Denmark
- Copenhagen, Capital Region of Denmark
- 26/11/2024
- Series B
- $135,000,000
Adcendo seeks to develop antibody-drug conjugates to create new medicines for cancer patients with a significant unmet need.
The company was founded in 2017 in Copenhagen, as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen.
- Industry Biotechnology Research
- Website https://adcendo.com/
- LinkedIn https://www.linkedin.com/company/adcendo/
Syntracts | $5,300,000 | (Oct 24, 2025)
GradBridge | $20,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
CipherOwl | $15,000,000 | (Oct 24, 2025)
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
Vermeer | $10,000,000 | (Oct 24, 2025)
GammaTime | $14,000,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Apriority Financial, Inc. | $2,300,000 | (Oct 24, 2025)
OneAM | $4,700,000 | (Oct 24, 2025)
🌱 Rightcharge | $2,131,920 | (Oct 24, 2025)
Tensormesh | $4,500,000 | (Oct 24, 2025)